person · Reporting owner
GROENHUYSEN WILHELMUS CM
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Operating Officer | June 28, 2024 | August 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 28, 2024 · Filed August 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 252,290 |
Reported balance
After 2024-06-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-28 · Grant · Acquired 1,055 · Balance 252,290 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptiNose, Inc.
Report date May 21, 2025 · Filed May 21, 2025
Section 16 reporting ended · disclosed 2025-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.60 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.70 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 3,566 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.25 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 2,133 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.10 · Expires 2031-06-09 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.75 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.00 · Expires 2029-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $337.50 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.00 · Expires 2027-10-12 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-05-21 · Disposition to issuer · Disposed 1,925 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2018 Filed Aug 28, 2018 20:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $40.03 | $8,005.00 |
DisclosureSEC source: 0001209191-18-048681 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,197 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 20:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 25,274 | $40.00 | $1,010,960.00 |
DisclosureSEC source: 0001209191-18-048681 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,397 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 20:05 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 31,179 | $37.67 | $1,174,603.35 |
DisclosureSEC source: 0001209191-18-048356 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,671 F1 · price: On August 22, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 31,179 shares in multiple trades at prices ranging from $37.50 to $37.90. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,300 | $37.50 | $86,250.00 |
DisclosureSEC source: 0001209191-18-047057 · doc4.xml · nonDerivative · entry 10 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,850 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100 | $37.60 | $3,760.00 |
DisclosureSEC source: 0001209191-18-047057 · doc4.xml · nonDerivative · entry 9 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,150 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 300 | $37.65 | $11,295.00 |
DisclosureSEC source: 0001209191-18-047057 · doc4.xml · nonDerivative · entry 8 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,250 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $37.55 | $7,510.00 |
DisclosureSEC source: 0001209191-18-047057 · doc4.xml · nonDerivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,550 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 500 | $37.75 | $18,875.00 |
DisclosureSEC source: 0001209191-18-047057 · doc4.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,750 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $37.70 | $7,540.00 |
DisclosureSEC source: 0001209191-18-047057 · doc4.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,250 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 68 | $37.80 | $2,570.40 |
DisclosureSEC source: 0001209191-18-047057 · doc4.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,450 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $38.00 | $7,600.00 |
DisclosureSEC source: 0001209191-18-047057 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,518 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 400 | $37.90 | $15,160.00 |
DisclosureSEC source: 0001209191-18-047057 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,718 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100 | $37.85 | $3,785.00 |
DisclosureSEC source: 0001209191-18-047057 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,118 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,790 | $35.05 | $62,739.50 |
DisclosureSEC source: 0001209191-18-045515 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,218 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,336 | $35.00 | $186,760.00 |
DisclosureSEC source: 0001209191-18-045515 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,008 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100 | $35.05 | $3,505.00 |
DisclosureSEC source: 0001209191-18-044941 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,344 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $35.03 | $7,005.00 |
DisclosureSEC source: 0001209191-18-044941 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,444 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 941 | $35.00 | $32,935.00 |
DisclosureSEC source: 0001209191-18-044941 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,644 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 20:39 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,100 | $37.05 | $40,755.00 |
DisclosureSEC source: 0001209191-18-044402 · doc4.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,585 F5 · price: On July 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,100 shares in multiple trades at prices ranging from $37.00 to $37.10. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 20:39 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,095 | $36.60 | $223,077.00 |
DisclosureSEC source: 0001209191-18-044402 · doc4.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,685 F4 · price: On July 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 6,095 shares in multiple trades at prices ranging from $36.00 to $36.95. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 20:39 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 34,385 | $35.20 | $1,210,352.00 |
DisclosureSEC source: 0001209191-18-044402 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,780 F3 · price: On July 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 34,385 shares in multiple trades at prices ranging from $35.00 to $35.90. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 20:39 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 17,437 | $34.44 | $600,530.28 |
DisclosureSEC source: 0001209191-18-044402 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,165 F2 · price: On July 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 17,437 shares in multiple trades at prices ranging from $34.00 to $34.98. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 20:39 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,710 | $33.86 | $125,620.60 |
DisclosureSEC source: 0001209191-18-044402 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,602 F1 · price: On July 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 3,710 shares in multiple trades at prices ranging from $33.70 to $33.95. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 20:10 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1,191 | $17.26 | $20,550.71 |
DisclosureSEC source: 0001209191-18-042134 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,312 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2018 through June 30, 2018. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 2, 2018. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 17:27 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 14,439 | $22.50 Strike: $22.50 | $324,877.50 |
DisclosureSEC source: 0001494650-18-000066 · wf-form4_152875241578846.xml · derivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,439 Underlying: Common Stock · 14,439 shares Expires 2028-06-06 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 7, 2019 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2019 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| May 14, 2018 Filed May 15, 2018 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 280 | $30.25 | $8,470.00 |
DisclosureSEC source: 0001209191-18-030229 · doc4.xml · nonDerivative · entry 10 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,121 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| May 14, 2018 Filed May 15, 2018 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $30.23 | $6,045.00 |
DisclosureSEC source: 0001209191-18-030229 · doc4.xml · nonDerivative · entry 9 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,401 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| May 14, 2018 Filed May 15, 2018 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $30.20 | $6,040.00 |
DisclosureSEC source: 0001209191-18-030229 · doc4.xml · nonDerivative · entry 8 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,601 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| May 14, 2018 Filed May 15, 2018 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,772 | $30.15 | $53,425.80 |
DisclosureSEC source: 0001209191-18-030229 · doc4.xml · nonDerivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,801 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| May 14, 2018 Filed May 15, 2018 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,927 | $30.10 | $148,302.70 |
DisclosureSEC source: 0001209191-18-030229 · doc4.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,573 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| May 14, 2018 Filed May 15, 2018 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100 | $30.08 | $3,007.50 |
DisclosureSEC source: 0001209191-18-030229 · doc4.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,500 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| May 14, 2018 Filed May 15, 2018 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,590 | $30.05 | $107,879.50 |
DisclosureSEC source: 0001209191-18-030229 · doc4.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,600 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| May 14, 2018 Filed May 15, 2018 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,008 | $30.00 | $300,240.00 |
DisclosureSEC source: 0001209191-18-030229 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,190 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| May 11, 2018 Filed May 15, 2018 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,700 | $30.03 | $81,067.50 |
DisclosureSEC source: 0001209191-18-030229 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,198 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| May 11, 2018 Filed May 15, 2018 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,693 | $30.00 | $200,790.00 |
DisclosureSEC source: 0001209191-18-030229 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,898 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 30,470 | $27.58 | $840,362.60 |
DisclosureSEC source: 0001209191-18-027646 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,591 F1 · price: On May 1, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 30,470 shares in multiple trades at prices ranging from $27.50 to $27.80. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 21:19 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 23,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-015002 · doc4.xml · derivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,148 Underlying: Ordinary Shares · 23,148 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 21:19 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 168,965 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-18-015002 · doc4.xml · derivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,965 Underlying: Ordinary Shares · 168,965 shares Expires 2028-02-27 F1 · derivative.exercise_date: Options to buy 168,965 ordinary shares will vest and become exercisable in equal installments on each of February 27, 2019, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 13,351 | $19.83 | $264,723.63 |
DisclosureSEC source: 0001209191-18-013422 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,061 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 22:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 43,334 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013422 · doc4.xml · derivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,666 Underlying: Ordinary Shares · 43,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 22:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 43,334 | $21.55 | $933,847.70 |
DisclosureSEC source: 0001209191-18-013422 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 21:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 31,132 | $21.02 | $654,375.96 |
DisclosureSEC source: 0001209191-18-003113 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,078 F3 · price: On January 9, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 31,132 shares in multiple trades at prices ranging from $21.00 to $21.05. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:11 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 310 | $15.05 | $4,663.95 |
DisclosureSEC source: 0001209191-18-003113 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,210 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2017 through December 31, 2017. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 3, 2017. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 21:06 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 26,264 | $21.03 | $552,313.54 |
DisclosureSEC source: 0001209191-18-002436 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,900 F2 · price: On January 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 26,264 shares in multiple trades at prices ranging from $21.00 to $21.075. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:06 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,404 | $21.00 | $50,484.00 |
DisclosureSEC source: 0001209191-18-002436 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,164 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:06 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $21.03 | $4,205.00 |
DisclosureSEC source: 0001209191-18-002436 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,568 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 12:40 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 28,879 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062324 · a4.xml · derivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,879 Underlying: Common Stock · 28,879 shares Expires 2027-10-11 F1 · derivative.exercise_date: The option vests and becomes exercisable over a three-year period commencing on October 12, 2017. Thirty-three percent (33%) of the option vests and becomes exercisable on October 12, 2018, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining two years of the three-year period, subject to continued service with the Issuer. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:46 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 2,484 | $6.67 | $16,575.73 |
DisclosureSEC source: 0001209191-17-044405 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,768 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2017 through June 30, 2017. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 3, 2017. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 130,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005216 · doc4.xml · derivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Ordinary Shares · 130,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Groenhuysen's continued employment through such dates. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Groenhuysen's continued employment through such dates. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 292,500 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0000899243-17-005216 · doc4.xml · derivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,500 Underlying: Ordinary Shares · 292,500 shares Expires 2027-02-22 F1 · derivative.exercise_date: Options to buy 292,500 ordinary shares will vest and become exercisable in equal installments on each of February 22, 2018, 2019, 2020 and 2021, subject to Mr. Groenhuysen's continued employment through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.